Résumé
Objective To explore the clinical efficacy of hidden blood loss after operation of proximal femoral nail anti-rotation (PFNA) for intertrochanteric fracture of femur of the elderly with Bazhen Decoction; To discuss the effects on short-term complications after operation. Methods Totally 87 patients with intertrochanteric fracture treated with PFNA were included in the study. The non-randomized controlled trial design was used to divide them into treatment group (44 cases) and control group (43 cases). Both groups were routinely given traction of the affected limbs and tibia, controlled hypertension, diabetes, anti-inflammatory analgesia, and low molecular weight heparin routine anticoagulation. The treatment group was treated with Bazhen Decoction, one dosage per day, continuous administration to 1 day before discharge. The bleeding volume, blood transfusion volume, hemoglobin, length of stay and short-term complications were observed in the two groups. Results The perioperative bleeding, volume and hospitalization time of the treatment group were all lower than those of the control group, with statistical significance (P<0.05). No patient needed blood transfusion in the treatment group, while two patients in the control group needed blood transfusion, with nine units. There was statistical significance between total blood transfusion volume in the two groups (P<0.05). There was no statistical significance in Hb level between the two groups 2 h after surgery (P>0.05). There was statistical significance in Hb level 12–24 h after surgery and 5 d after surgery between the two groups (P<0.05). There was no statistical significance in short-term complications between the two groups (P>0.05). Conclusion Bazhen Decoction can improve Hb level and reduce recessive blood loss and total blood loss of elder patients with femoral fractures treated with PFNA, which is also good for postoperative rehabilitation.
Résumé
OBJECTIVE:To investigate the clinical efficacy and safety of modified Bazhen decoction combined with antibiot-ics in the treatment of postpartum fever with qi-blood deficiency. METHODS:Totally 94 cases of postpartum fever with qi-blood deficiency selected from our hospital during Dec. 2014-Jun. 2016 were divided into control group and observation group according to random number table,with 47 cases in each group. Control group was given Cefazolin sodium for injection 3 g added into Sodi-um chloride injection 250 mL,ivgtt,bid;and given Azithromycin for injection 250 mg added into Sodium chloride injection 250 mL,ivgtt,bid if body temperature did not drop for consecutive 2 days;the patients with body temperature over 38.5 ℃ were giv-en Compound aminophenazone and barbital injection 2 mL intramuscularly. Observation group was additionally given modified Ba-zhen decoction on the basis of control group. Treatment course of 2 groups lasted for 5 d. Clinical efficacies were compared be-tween 2 groups as well as white blood cell count,plasma C reactive protein(CRP),plasma viscosity and fibrinogen(Fib)before and after treatment. The antipyretic time,hospitalization time and the occurrence of ADR were observed in 2 groups. RESULTS:The total response rate of observation group was 95.75%,which was significantly higher than 78.72%of control group,with statis-tical significance(P0.05). After treatment,white blood cell count,CRP,plasma viscosity and Fib of 2 groups were decreased significantly,and the observation group was significantly lower than the control group,with statistical significance(P<0.05). The antipyretic time and hospitalization time of observation group were shorter than those of control group,with statistical significance (P<0.05). The incidence of ADR in observation group was 6.38%,which was significantly lower than 23.40% of control group,with statistical significance (P<0.05). CONCLUSIONS:Modified Bazhen decoction combined with antibiotics in the treatment of postpartum fever with qi-blood deficiency can significantly improve inflammation status and plasma viscosity,and speed up defervescence with good safety.
Résumé
Objective To observe the effect of modified Bazhen Decoction ( MBD) on bone marrow fibroblast growth factor-1 ( FGF-1) in chronic aplastic anemia ( CAA) patients. Methods Sixty cases of CAA were randomly divided into treatment group and control group, 30 cases in each group. Both groups were given conventional western medicine such as oral use of Stanozolol and Ciclosporin, and additionally, the treatment group received oral use of MBD. Six months constituted one treatment course for both groups. After treatment, the clinical efficiency in western medicine field and on Chinese medical syndromes was evaluated in both groups. The changes of peripheral hemogram, adverse reaction, and FGF-1 in the bone marrow of both groups were also monitored. Results ( 1) Clinical efficacy in western medicine field was 80.0% in the treatment group, and was 66.7%in the control group (P<0.05). (2) The total effective rate on Chinese medical syndromes was 100.0% in the treatment group, and was 83.3%in the control group (P<0.05). (3) After treatment, the scores of symptoms were decreased in both groups (P<0.05 or P<0.01 compared with those before treatment), and the decrease in the treatment group was superior to that in the control group (P<0.05). (4) Peripheral white blood cell (WBC) count, hemoglobin (HGB) content and platelet (PLT) count as well as bone marrow FGF-1 were increased in both groups after treatment (P<0.01 compared with those before treatment), and the increase of WBC, HGB, PLT and FGF-1 in the treatment group was superior to that in the control group (P<0.05). (5) In the aspect of the adverse reaction, the treatment group had 2 cases of hepatic fucntion injury, and one case of acne and hairiness; the control group had 2 cases of gum hypertrophy, 5 cases of hepatic function injury, and 4 cases of acne and hairiness. The control group had higher incidence of adverse reaction ( P<0.05). Conclusion MBD exerts certain therapeutic effect for CAA, and one of the possible mechanisms is related with the regulation of FGF-1 level.